Reviewing Stevanato Group (NYSE:STVN) and SI-BONE (NASDAQ:SIBN)

SI-BONE (NASDAQ:SIBN) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Recommendations

This is a breakdown of current recommendations for SI-BONE and Stevanato Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0	0	6	0	3.00
Stevanato Group	0	1	5	0	2.83

SI-BONE currently has a consensus price target of $23.00, suggesting a potential upside of 34.66%. Given SI-BONE’s stronger consensus rating and higher probable upside, research analysts plainly believe SI-BONE is more favorable than Stevanato Group.

Profitability

This table compares SI-BONE and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SI-BONE	-23.82%	-22.51%	-16.53%
Stevanato Group	10.47%	9.86%	5.79%

Earnings & Valuation

This table compares SI-BONE and Stevanato Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$157.04 million	4.56	-$43.34 million	($0.92)	-18.57
Stevanato Group	$1.17 billion	5.69	$157.62 million	€0.47 ($0.48)	46.94

Stevanato Group has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

98.1% of SI-BONE shares are owned by institutional investors. 3.9% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

SI-BONE has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Summary

Stevanato Group beats SI-BONE on 8 of the 14 factors compared between the two stocks.

About SI-BONE

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.